(Q35592786)

9 August 2017

1 reference

title

Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease (English)

1 reference

9 August 2017

1

John G Nutt

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

9 August 2017

published in

Experimental Neurology

1 reference

9 August 2017

volume

184

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

9-13

1 reference

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

The Long-Duration Action of Levodopa May Be Due to a Postsynaptic Effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Levodopa therapy: consequences of the nonphysiologic replacement of dopamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Kinetic-dynamic relationship of oral levodopa: Possible biphasic response after sequential doses in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Modification of Parkinsonism--chronic treatment with L-dopa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Aromatic Amino Acids and Modification of Parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Early morning off-medication dyskinesias, dystonia, and choreic subtypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Dopamine autoreceptor function is lost in advanced Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

The mechanisms of action of L-dopa in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Continuous and intermittent levodopa differentially affect basal ganglia function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Comparison of motor response to apomorphine and levodopa in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Loss of regulation by presynaptic dopamine D2 receptors of exogenous L-DOPA-derived dopamine release in the dopaminergic denervated striatum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Pathogenesis of dyskinesias in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Evolution of the response to levodopa during the first 4 years of therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Short- and long-duration responses to levodopa during the first year of levodopa therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Does an inhibitory action of levodopa contribute to motor fluctuations?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Interactions between deep brain stimulation and levodopa in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Dopamine metabolism in the central nervous system after discontinuation of L-dopa therapy in patients with Parkinson disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Dystonia in Parkinson's disease: clinical and pharmacological features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

DOPA effects on motility in mice; Potentiation by MK 485 and dexchlorpheniramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Levodopa induces dyskinesias in normal squirrel monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900304-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-4886(03)00304-2

1 reference

9 August 2017

1 reference